Thiazolidinediones, including pioglitazone, can cause or exacerbate congestive heart failure (CHF) in some patients. After initiation of pioglitazone
Pioglitazone: Belongs to the class of Patient with oedema, risk factors for CHF (e.g. previous MI, symptomatic coronary artery disease).
Congestive heart failure (CHF) risk. Also see Black Box Warnings regarding CHF risk of pioglitazone; The EXAMINE (Examination of Cardiovascular Outcomes with
Pioglitazone has a boxed warning for the risk of congestive heart failure. In studies, congestive heart failure (CHF) was rare in people taking pioglitazone
Pioglitazone, like other thiazolidinediones, can cause or exacerbate congestive heart failure (CHF) in some patients. In post-marketing experience with
Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR ). Without CHF: initially 15mg or 30mg once daily; max 45mg once daily. With CHF (NYHA Class I or II
congestive heart failure (CHF) than those who do not; the incidence of CHF is similar with the use of pioglitazone (Actos), troglitazone (Rezulin), or
Pioglitazone drug interactions. There are 337 drug interactions with pioglitazone. Pioglitazone disease interactions. There are 9 disease interactions with pioglitazone which include: CHF; type I diabetes; bladder cancer; edema; liver disease; macular edema; premenopausal anovulation; weight gain; anemia
Non-fatal heart failure. In PROACTIVE, pioglitazone was associated with increased risk for CHF (figure 2). In the other 40 trials reporting
BTW. Standalone CHF taking down an otherwise healty person like that??? No afib, no obesity, no alcoholism, no bundle blockage or left side failure??